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Summary 
Myometrial tissue rings from postpartum rats (24 h after delivery) were 
studied in vitro by electric field stimulation, and the a,/&ulrenoceptor ratio was 
determined by a radioligand binding technique. Pregnancy-denervated uterine 
rings were stimulated by long-duration pulses (100 ms). The contractions were 
inhibited by &-agonists (terbutaline and fenoterol) and a-antagonists 
(phentolamine, urapidil and yohimbine) in a concentration-dependent manner. 
Their effects were not altered by the adrenergic neuron-blocking agent bretylium. 
The a-antagonists (except phentolamine) elicited the same maximal inhibition as 
the &-agonists. Receptor assays revealed that the al/pz ratio was about 2 in the 
measured uteri. It was concluded that the inhibitory effects of a-antagonists and 
Pz-agonists are mediated via non-synaptic adrenoceptors of the denervated 
postpartum rat uterus. The same inhibitory activity could be explained by the 
greater amount of a-receptors. It is believed that this is the first functional proof 
of the existence of non-synaptic a,-adrenoceptors in smooth muscle. 
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The adrenergic part of the autonomic nervous system plays an important role in the 
regulation of the motor activity of the uterus (1). This is reflected by clinical practice, Pz-agonists 
being among the most frequently used tocolytic drugs. It is well known that during pregnancy the 
adrenergic innervation of the uterus undergoes a significant change in many species, e.g. guinea 
pig, rabbit and human (2,3,4). There is also a significant decrease in the number of adrenergic 
nerves in the final period of pregnancy of the rat, while the adrenergic 
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nerve ends and noradrenaline vesicles disappear during delivery (5). There is a similar 
phenomenon in humans (6). However, the sensitivity of the adrenoceptors of the surface of the 
smooth muscles remains or increases despite desympathization (2). 
While the role of the P-receptors of the denervated myometrium during pregnancy has 
been demonstrated by clinical experience and results in several articles knowledge of the role of 
a-receptors is limited. There is likewise very limited information as to whether adrenegic 
receptors in pregnancy, despite denervation, have connections with nerve ends or function 
independently from any synaptic junction. The latter is suggested by histological studies relating 
to P-receptors. One aim of our study was to clarify the role of a-receptors in the regulation of the 
contractility of the pregnant uterus as compared to P-receptors. A further aim was to prove the 
synaptically independent function of adrenergic receptors in the pregnant myometrium. Our 
experiments were carried out on the isolated rat uterus by electric field stimulation (EFS) and on 
rat uterus membrane preparations by a radioreceptor binding assay. 
Methods 
Uterus preparation and EFS 
Uteri were removed from Sprague-Dawley rats (200-250 g) 24 h after delivery. Muscle 
rings 0.5 cm long were sliced from the uterine horns and mounted vertically between two 
platinum electrodes in an organ bath containing 10 mL de Jongh solution (in mM: 137 NaCI, 3 
KCl, 1 CaCl*, 1 MgCI,, 12 NaHC03, 4 NaH2P04, 6 glucose; pH: 7.4). The organ bath was 
maintained at 37 “C and carbogen (95% O2 + 5% CO,) was bubbled through it. After mounting, 
the rings were equilibrated for about 1.5-2 h before experiments were undertaken. After the 
incubation period. rhythmic contractions were elicited by a digital, programmable stimulator (ST- 
02, Experimetria Ltd. U.K.) using square pulses with a duration of 100 ms every 75 s at 40 V. 
The tension of the myometrial rings was measured with a strain gauge transducer (SG-02, 
Experimetria Ltd. U.K.) and recorded by an ISOSYS Data Acquisition System (Experimetria Ltd. 
U.K.). Cumulative concentration-response curves to &-agonists and a-antagonists have been 
constructed in each experiments. Areas under curves were evaluated and EC5,, and maximal 
inhibition values were calculated with the Graphit 3.01 computer program. The maximal 
contractile response of each ring to electric field stimulation was used as reference and set at 
100%. 
Radioreceptor binding assays 
Radoligand binding experiments were carried out on the membrane preparation of a rat 
uterus postpartum (24 h after delivery) in Tris-HCI buffer (in mM: 50 Tris-HCI, 3 MgCl,, 1 
ascorbic acid; pH: 7.4). The uteri were removed and then were homogenized in twenty volumes 
(wt/vol) of ice-cold buffer (10 mM TRIS-HCI, 1 mM EDTA, 0.6 mM MgCI,, 0.25 M sucrose, pH 
7.4) with Ultra Turrax T25 (Jar&e & Kunkel) homogenizer, the suspension was filtered on four 
layers of gauze and centrifuged with Centrikon T-42K centrifuge (40,000 x g, 4°C 20 min). After 
the centrifugation the pellet was resuspended in 5x volumes of buffer. The membranes were 
stored in liquid nitrogen. 
The reaction mixture contained 100 pl tritiated ligand, IO0 pl membrane preparation (-0.3 
mg/ml protein) and 100 p1 unlabelled ligand (10 PM) for non-specific binding or 100 ~1 Tris-HCl 
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buffer for total binding. Incubations were started by addition of the membrane suspension and 
continued in a shaking water bath until a steady-state was achieved (30 “C, 30 min). The reaction 
was terminated by rapid filtration on a Skatron 11019 cell harvester through Whatmann GFiC 
filters and washed with 10 ml of ice-cold TRIS-HCI (pH 7.4) buffer. The bound radioactivity was 
determined in a HighSafe@ scintillation cocktail in a Wallac 1409 liquid scintillation counter. The 
total binding was defined as that measured in the absence of a competing agent. Non-specific 
binding was determined in the presence of 10 FM unlabelled prazosine for a,- and 
dihydroalprenolol for P-adrenergic receptors. All assays were carried out at least three times in 
duplicate, and values are given as means XSEM. The binding capacity (B,,,) and Kd of values 
were calculated according to Rosenthal (7). Competition data was analyzed using the program 
LIGAND (8), utilizing a nonlinear least squares fitting algorithm. 
Materials 
The following drugs were used for EFS experiments: fenoterol (BoehringerJngelheim. 
Germany), phentolamine (Ciba-Geigy A.G., Germany), terbutaline (ASTRA, Sweden), urapidil 
(Byk Gulden, Germany), and yohimbine (Sigma-Aldrich Ltd., Hungary). Drugs were added to the 
organ bath in a volume of 100 PL aqueous solution. [3H]Prazosine (72 CiimM) and 
fHJdihydroalprenolol(94 Ci/mM) (Amersham, England) were used in the receptor assays. 
Results 
The EFS-stimulated uterine contractions were inhibited concentration-dependently by the 
selective P,-agonists terbutaline and fenoterol in the range of 2.5x10‘7-3.2x10~5 M (Figure 1). 
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Fig. 1 
Effects of &-agonists and a-antagonists on uterine 
contractions in vitro.The data are the averages of the results 
from six experiments ?Y S.E.M. Fenoterol (x), terbutaline (e), 
yohimbin (0). urapidil (f), phentolamine (U). 
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The affinity of fenoterol was approximately twice that of terbutaline. However, there were no 
differences in maximal inhibitory activity between the two drugs (Table I). 
TABLE I 
ECsO and maximal inhibition values of &,-agonists and a-antagonists on postpartum rat 
myometrium 
Drug name ECsO value [M]+SEM. Maximal inhibition [%I+ SEM. 
fenoterol 8.5x10~‘+1.0x10-’ 60.8fl.l 
terbutaline 2.1x1O-6+3.Ox1O-7 63.5f1.4 
phentolamine 6.2~10~~+1.3~10-~ 44.7?2.0 
urapidil 1.0x10-4~9.7x10-6 63.5k1.4 
yohimbine 7.5x10-5~1.9x10-’ 63.Ok2.9 J 
EC&: concentration causing 50% of the maximal inhibitory effect 
Similarly to the P-agonists, the non-selective a-antagonist phentolamine, the selective a, - 
antagonist urapidil and the selective a+ntagonist yohimbine in the concentration range 2.5x1 O“- 
3.2x1 0” M decreased the uterine contractions (Figure 1). There were no significant differences in 
affinity between the three drugs, but the maximal inhibition by phentolamine lagged about 20% 
behind those of urapidil and yohimbine (Table I). The effects of the P-agonists and a-antagonists 
were also measured in the presence of 3x 1 O‘6 M bretylium, but no changes were found. 
In the receptor binding assays, we found that the maximal number of binding sites (B,,,) 
for the at-receptors was 720+54 fmol/mg protein, while that for the P-receptors was 337f33 
fmol/mg protein. The calculated a,@ ratio was 2.13. 
Discussion 
Pregnancy-denervated rat uterine muscle was investigated by EFS. The appropriate pulse 
parameters prove the separated stimulation of the tissue innervation and the smooth muscle. The 
fast Na+-channels of the transmural nerves can be selectively stimulated by a short pulse duration 
(0.5-5.0 ms), as can the slow Ca*‘-channels of the smooth muscle by a long pulse duration (60- 
133 ms) (9). Therefore, the 100 ms pulse duration used in our experiments precludes the 
possibility of any significant nerve excitation. This is supported by the histological facts 
mentioned earlier. Addition of the adrenergic blocking agent bretylium to the organ bath did not 
alter the intensity of the contractions which suggests that endogenous noradrenaline has no role in 
the mechanism of stimulated contractions. The postpartum uterus 24 h after delivery is 
histologically equivalent to the last-term pregnant uterus because the regeneration of the 
sympathetic nerves is very slow: it takes about 1 month (10). These facts lead us to suggest that 
our model is applicable for the investigation of nerve-independent, smooth muscle joint 
adrenoceptors of the myometrium. 
We found that P,-agonists and a-antagonists inhibited the rhythmic uterine contractions 
elicited by EFS. This effects of the Pz-agonists terbutaline and fenoterol could be connected with 
their intracellular CAMP-increasing effects (11) The relaxant effect of the selective a,-antagonist 
yohimbine could play a role in the blockade of the a,-receptor-linked Ca*‘-channels (12), 
besides the increase in the CAMP level (13). It is very probable that the inhibitory effect of the 
selective al-antagonist urapidil can be explained by inhibition of those Ca**-channels 
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functionally coupled to the al-receptor subtypes (14). A further explanation may be given the 
inhibition of endogenous ATP-release by the al-receptor blockers (15). The effect of the non- 
selective a-blocker phentolamine probably involves the mechanisms of urapidil and yohimbine 
mentioned above. 
The rather high effective concentration of Pz-agonists (2.5x1~‘-3.2~1@~ M) can be 
explained by the effect of gestational age on tachyphylaxis in the pregnant rat myometrium (16). 
However, we have not clear explanation of high effective concentration of a-blockers (2.5x1u5- 
3.2~10‘~ M). The clarification of this question requires further investigations. 
The similar in vitro inhibitory activities of the &-agonists, urapidil and yohimbine are 
surprising in view of the fact that &-agonists are so effective in the clinical practice of tocolysis 
that a-blocker are not used at all at present. The equivalent inhibitory actions of the two groups 
could be explained by the receptor binding assay results in which we demonstrated a higher 
density of a,-receptors as compared to that of P,-receptors. It is known that the a,/a, ratio in the 
rat uterus is about 1 (17). 
Our results lead us to suggest that the effects of P,-agonists and a-antagonists are 
mediated through the non-synaptic adrenoceptors in the postpartum rat uterus. A number of 
papers have been published on the extrasynaptic functions of a2- and P2-receptors (18,19,20). 
However, a,-receptors are currently considered to be situated only intrasynaptically (21). Our 
results suggest that the non-synaptic a,-adrenoceptors play an important role in the regulation of 
the pregnant rat uterus and in delivery. This is supported by the fact that a,-blockers (prazosine 
and urapidil) inhibited spontaneous postpartum rat uterus contractions in vivo (22). To best of our 
knowledge, our results afford the first functional proof of the existence of non-synaptic a,- 
adrenoceptors in smooth muscle such as the postpartum rat myometrium. 
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